Event Overview

Chimeric antigen receptor (CAR) T cells hold great promise for targeting and fighting cancer. However, their efficacy in solid tumors has been below expectations, as the tumor microenvironment (TME) limits their infiltration and produces a range of immune-inhibitory molecules to deactivate T cells. Researchers are developing new strategies to enhance CAR-T cell therapy for solid tumors by disrupting the TME and promoting T cell persistence. In this webinar brought to you by IsoPlexis, Katie McKenna will discuss how she uses CAR-T cells in combination with mesenchymal stromal cells that deliver engineered adenoviruses to stimulate the immune response in the TME.

Topics to be covered

  • Targeting non-small cell lung cancer using a cell carrier system to deliver an oncolytic and immunostimulatory adenovirus
  • Efficacy of oncolytic virotherapy in 3D cell culture and in vivo
  • Assessing T cell functionality with single-cell proteomics
  • Tuesday, April 27, 2021
    2:30 - 3:30 PM Eastern Time

    Meet the speaker

    Katie McKenna, PhD
    Postdoctoral Fellow
    Center for Cell and Gene Therapy
    Baylor College of Medicine
    Texas Children’s Hospital
    Methodist Hospital


    Register Now

    Harnessing Single-Cell Multi-Omic Energy States for Integrated Cancer Biology Feb 16, 2021

    You must have Javascript and Cookies enabled to access this webcast.

    Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.